Abstract:
The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined herein; X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; and R3 is —CO2Rd, —CO2M, —OH, —NHRd, —SO2Rd, —NHCONHRd, optionally-substituted amidino or optionally-substituted guanidino; or R3—X— is hydrogen or an electron pair; R4 is oxygen or —NR9R10; R5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; and R6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with Ra.
Abstract translation:本发明涉及新的1,4-二氮杂,其药物组合物及其作为HDM2-p53相互作用抑制剂的用途。 化合物具有式I:或其溶剂合物,水合物或其药学上可接受的盐; 其中:R 1,R 2,R 9,R 10,R SUP, >,R d和M在本文中定义; X是二价基团:烷烃,环烷烃,任选取代的芳烃,任选取代的杂芳烃,任选取代的芳基烷烃或任选取代的杂芳基烷烃; 和R 3是-CO 2 R 2,-CO 2 M,-OH,-NHR 0 任选取代的脒基或任选取代的胍基;其中R 1,R 2,R 3,R 4, 或R 3 -X-是氢或电子对; R 4是氧或-NR 9 R 10; R 5是环烷基,芳基,杂芳基,环烷基烷基,芳烷基,杂芳基烷基或饱和或部分不饱和的杂环,其各自任选被取代; R 6和R 8独立地是氢,烷基,环烷基,芳基,杂芳基,饱和或部分不饱和的杂环,环烷基烷基 ,芳烷基或杂芳基烷基,其各自任选被取代; 或R 6和R 7与它们所连接的碳原子一起形成3-至7-元碳环,任选地被R 1取代1至3倍, SUP> a SUP>。
Abstract:
The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
Abstract:
The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
Abstract:
The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
Abstract:
The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
Abstract:
A web application that enables access to a client's specific account transaction detail. The charge transaction detail can include anything related to charge or credit card transactions including travel transaction detail, corporate card detail and corporate purchasing card detail. The transaction detail can be captured from many sources and can include third party data. The clients can use a web application and web page to access the account data and create report views of the information. The system can also includes a create a report capability, which allows users to add filters and data elements to an existing report format and create a report specific to their needs and data.
Abstract:
The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines, which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
Abstract:
The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently —C(O)—, —CH2— or —C(S)—; R1, R2, R3, R4, R7, R8, Rb, Rc, Rd and M arm defined herein; R5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R9 is cycloalkyl: aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is —(CH2)n—CO2Rb, —(CH2)m—CO2M, —(CH2)i—OH or —(CH2)j—CONRcRd n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
Abstract translation:本发明涉及新的1,4-苯二氮卓类药物,其药物组合物及其作为HDM2-p53相互作用抑制剂的用途。 化合物具有式I:或其溶剂合物,水合物或其药学上可接受的盐; 其中:X和Y独立地为-C(O) - , - CH 2 - 或-C(S) - ; R 1,R 2,R 3,R 4,R 7, R 8,R b,R c,R d,R d和M臂; R 5是氢,烷基,环烷基,任选取代的芳基,任选取代的杂芳基,任选取代的芳烷基,任选取代的杂芳烷基,羧基烷基,烷氧基羰基,烷氧基羰基烷基,氨基羰基,氨基羰基烷基,烷基氨基羰基或烷基氨基羰基烷基; R 6是环烷基,芳基,杂芳基,环烷基烷基,芳烷基,杂芳基烷基或饱和或部分不饱和的杂环,其各自任选被取代; R 9是环烷基:芳基,杂芳基,饱和或部分不饱和的杂环,环烷基(烷基),芳烷基或杂芳基烷基,其各自任选被取代; 和R 10是 - (CH 2)n - - - - - - (CH 2)n - , - (CH 2)2 - , - M 2 - , - (CH 2) -OH或 - (CH 2 CH 2)n -CONR C n R n为0-8 ,m为0-8,i为1-8,j为0-8。